Roquefort Therapeutics targets cancel treatment with £32m deal
LONDON: Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m…
Featured
Seventy new homes for elderly step closer to construction
AI Living redefines housing as governments confront ageing future
Best retirement housing design for Global Awards shortlisted
Innovation Report on Modular Construction and Purpose Built housing published
Developer set to progress four extra care housing schemes
New public housing development for major public site
Innovation
